Suppr超能文献

肺癌细胞系中拓扑异构酶II水平与对拓扑异构酶II抑制剂耐药性之间的关系。

Relationship between topoisomerase II levels and resistance to topoisomerase II inhibitors in lung cancer cell lines.

作者信息

Houlbrook S, Harris A L, Carmichael J, Stratford I J

机构信息

Molecular Oncology Laboratories, Imperial Cancer Research Fund, John Radcliffe Hospital, Oxford, U.K.

出版信息

Anticancer Res. 1996 Jul-Aug;16(4A):1603-10.

PMID:8712677
Abstract

Topoisomerase II is a key target of many anticancer drugs used to treat lung cancer. We measured the expression of topoisomerase II alpha and beta mRNA's and also the levels of cellular topoisomerase II alpha and beta protein and concluded that topoisomerase II alpha levels are important in cellular resistance to the topoisomerase II inhibitors examined. This can be clearly seen in pairs of matched cell lines. However, when looking at a panel of cell lines with a range of histological types the importance of the enzyme can be masked by other cellular characteristics such as repair and detoxification mechanisms.

摘要

拓扑异构酶II是用于治疗肺癌的许多抗癌药物的关键靶点。我们测量了拓扑异构酶IIα和β mRNA的表达以及细胞拓扑异构酶IIα和β蛋白的水平,并得出结论,拓扑异构酶IIα水平在细胞对所检测的拓扑异构酶II抑制剂的抗性中很重要。这在配对的匹配细胞系中可以清楚地看到。然而,当观察一组具有一系列组织学类型的细胞系时,该酶的重要性可能会被其他细胞特征(如修复和解毒机制)所掩盖。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验